Jesus Rodriguez-Pascual* and Antonio Cubillo Pages 81 - 85 ( 5 )
Background: Identification of clinical and molecular biomarkers to predict dynamic response or monitor in real-time the efficacy of antiangiogenic therapy represents a major point in the treatment of patients with advanced colorectal cancer. Several studies have been conduced to identify some predictive biomarkers to select patients who will benefit from bevacizumab, the most widely used antiangiogenic monoclonal antibody.
Conclusion: After a decade since the introduction of bevacizumab, no effective predictive biomarkers are available in routine clinical practice. In this review, we summarized the potential candidate dynamic biomarkers that may play a role in this setting.
Colorectal cancer, bevacizumab, biomarkers, angiogenesis, chemotherapy, metastatic disease.
Centro Integral Oncologico Clara Campal (CIOCC), Madrid, Centro Integral Oncologico Clara Campal (CIOCC), Madrid